2008 Annual Meeting
(598e) Systems Biology Analysis of Neurodegenerative Diseases
Authors
The interaction data including protein-protein, protein-DNA interactions of both human and mouse were collected from public databases such as NCBI. The microarray gene expression profiles of both ALS patients and mice model were obtained from GEO database. The interaction data was used to reconstruct the underlying network and gene expression profiles were applied to identify the causal pathways that were transcriptionally differentiated in ALS patients or mice model. Simulated annealing was applied to search the subnetwork with the highest score based upon transcription profile. Not surprisingly, human studies revealed an enriched pattern of cell death, neurodegeneration and inflammation. However, human samples were obtained from the patients at the end stage of the disease, which may not be informative about the causal pathways. To obtain a more complete picture of which pathways are altered within degenerating motor neurons and identify which stage of the disease these changes happen, we obtained time course gene expression profile from transgenic SOD93A mice model. Three specific stages of disease progression were evaluated, correlating with the initiation of molecular changes (60 days), the onset of muscle weakness and motor neuron loss (90 days) and late stage time point of robust motor neuron pathology (120 days). The early time point analysis indicated that the pathways such as insulin signaling, EGF signaling, PI3K-AKT, TGF signaling and antioxidant ARE-NRF2 pathway were involved in the initiation of the disease. The late stage of the mice model resembles the human studies with pathways such as apoptosis being enriched. The transcription factors and microRNAs enriched in the identified gene modules were also studied. Potential therapeutic targets were predicted and validated either with published literature or with experiments. It is also discussed how to design combinations of multiple therapeutic targets perturbations to ameliorate ALS phenotype.